Tharimmune Inc.: Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
centerforbiosimilars26d
No IBD Activity Changes Following Switch From Biosimilar to Originator Infliximab
Most patients (87%) did not develop ADAs during the study. Dosing of infliximab at week 48 compared to baseline was stable for 40% of patients, lower for 39% and higher for 21% of patients. The ...